newsfilter
← Latest News
Business Wire·

Silence Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights

‒ Presented Updated SANRECO Phase 1 Data at EHA 2025 Further Supporting Potential for Divesiran as First-in-Class siRNA in PV ‒ SANRECO Phase 2 Study On-Track for Complete Enrollment by Year-End 2025 Silence